Sterility Testing for Peptides: Microbial Safety and Quality Assurance Standards
Purity tells you the sample is clean chemically. Sterility tells you it's safe biologically. These are not the same thing — and for any peptide used in an injectable, clinical, or high-contact application, the difference is the line between safe use and a serious adverse event. This guide covers everything you need to know about sterility testing for peptides, from USP ⟨71⟩ methodology to what a legitimate sterility test certificate must document.
- What Is Sterility Testing for Peptides?
- Why Sterility Is a Safety Issue — Not Just a Quality Issue
- USP ⟨71⟩: The Regulatory Framework for Peptide Sterility Testing
- How Peptide Sterility Testing Works: Step-by-Step
- The Two Culture Media: FTM and SCDM Explained
- The 14-Day Incubation Protocol and Observation Schedule
- Sterility Test Methods: Membrane Filtration vs Direct Inoculation
- Sterility vs Endotoxin vs Bioburden Testing: Critical Differences
- Route of Administration and Sterility Risk Levels
- What a Complete Peptide Sterility Test Report Must Contain
- How PeptideValidation.com Handles Sterility Testing
- Common Sterility Testing Mistakes to Avoid
- Who Needs Sterility Testing for Peptides?
- Benefits of Third-Party Peptide Sterility Testing
- Frequently Asked Questions
What Is Sterility Testing for Peptides?
Sterility testing is the microbiological quality test that determines whether a peptide product is free from viable microbial contamination — bacteria, fungi, and yeast — at the time of testing. It is the biological safety gate that chemical analysis methods (HPLC, LC-MS) are inherently unable to perform, because those methods detect molecules, not living organisms.
A synthetic peptide can have 99% HPLC purity and a verified molecular mass by LC-MS and still be contaminated with Staphylococcus aureus, Pseudomonas aeruginosa, Aspergillus fumigatus, or any number of other pathogenic microorganisms at levels that would cause serious harm in injectable or clinical use. Chemical purity tests detect none of this. Only sterility testing does.
The procedure works by taking a representative sample from the peptide batch, inoculating it into culture media formulated to support the growth of a wide range of microorganisms, and observing whether any growth occurs over a defined incubation period. No growth confirms that the batch passed sterility testing for that sample size. Growth triggers investigation, retesting, and potentially batch rejection.
Injectable peptides administered without sterility verification carry real risks: local infection at the injection site, bacteremia (bacteria in the bloodstream), pyrogenic reactions from microbial metabolites, and in severe cases, sepsis. These are not theoretical risks — they are documented consequences of administering non-sterile injectable compounds. Endotoxin testing alone is not a substitute for sterility testing; a product can pass endotoxin limits while still containing viable microorganisms that will grow post-administration.
Why Sterility Is a Safety Issue — Not Just a Quality Issue
The distinction matters enormously for how you approach sterility testing and what you communicate to customers and regulatory authorities. Failing an HPLC purity test means the product doesn't meet its chemical specification. Failing a sterility test means the product could harm the person using it — potentially severely and immediately.
Microbial contamination in peptide products enters through multiple routes during manufacture, handling, packaging, and reconstitution:
- Environmental contamination — Non-sterile manufacturing environments introduce airborne organisms during lyophilization or filling operations
- Personnel contamination — Human skin, breath, and hair carry Gram-positive bacteria (Staphylococci, Micrococci) that contaminate open products
- Container/closure failure — Compromised vial septa, cracked glass, or degraded closures allow post-sterilization contamination
- Water-borne organisms — Pseudomonads and other Gram-negative organisms thrive in aqueous solutions and pharmaceutical water systems
- Raw material contamination — Amino acid raw materials and excipients may carry bioburden that survives into the final product
- Cross-contamination during filling — Non-validated filling processes transfer organisms from equipment surfaces to the product
No sterility test can guarantee that a batch is sterile. This is a mathematical reality: a test can only sample a portion of the batch, and contamination may not be evenly distributed. What sterility testing does is provide statistical confidence that a batch is free from contamination at the detection level of the test. The broader sterility assurance program — manufacturing environment controls, validated sterilization processes, container/closure integrity, personnel hygiene protocols — is what actually produces sterile products. The USP ⟨71⟩ sterility test is the verification step, not the mechanism of sterility.
USP ⟨71⟩: The Regulatory Framework for Peptide Sterility Testing
USP ⟨71⟩ (Sterility Tests) is the United States Pharmacopeia general chapter that establishes the official methodology, media requirements, incubation conditions, and interpretation criteria for sterility testing of pharmaceutical products in the United States. It is the primary regulatory reference for sterility testing of peptides in compounding, pharmaceutical development, and research contexts.
Key requirements established by USP ⟨71⟩ include:
- Two culture media — Fluid Thioglycollate Medium (FTM) and Soybean-Casein Digest Medium (SCDM) must both be used, as each targets a different spectrum of microorganisms
- Incubation period — A minimum of 14 days (not 7, not 10 — 14 days is the USP minimum for complete incubation)
- Temperature requirements — FTM at 30–35°C; SCDM at 20–25°C
- Membrane filtration preference — USP ⟨71⟩ requires the membrane filtration method as the method of choice when the product properties permit; direct inoculation is the alternative
- Sample quantity — Defined by the type of product and batch size; for peptide solutions, typically 1–10% of the batch or a specified minimum number of containers
- Method suitability testing — The method must be validated to demonstrate that the product itself does not inhibit microbial growth (bacteriostasis/fungistasis testing)
- Growth promotion testing — Media must be verified to support growth of specified challenge organisms before use in routine testing
USP ⟨71⟩ is broadly harmonized with the European Pharmacopoeia (Ph. Eur. 2.6.1 Sterility) and the Japanese Pharmacopoeia (JP General Tests 4.06). The core methodology — two media, 14-day incubation, membrane filtration preference — is consistent across all three, making USP ⟨71⟩-compliant sterility data generally acceptable in international regulatory filings with appropriate supporting documentation.
How Peptide Sterility Testing Works: The Complete Process
Batch Sampling and Sample Size Determination
The number of containers to test is specified by USP ⟨71⟩ Table 1 and depends on batch size and product type. For batches of more than 200 vials of a sterile product, at least 10 containers must be sampled. The sample must be representative of the batch — taken from multiple positions within the batch rather than a single location. Inadequate sampling size is a common deficiency in non-validated sterility testing programs.
Aseptic Sample Preparation Under Laminar Airflow
All sample handling and media inoculation must be performed in an aseptic environment — either a Grade A (ISO 5) laminar airflow workstation or an isolator system. The intent is to prevent contamination of the test itself from the environment or analyst, which would produce a false-positive result. Any laboratory claiming to perform valid sterility testing without a documented, validated cleanroom environment is performing the test incorrectly. This is non-negotiable under USP ⟨71⟩.
Method: Membrane Filtration (Preferred) or Direct Inoculation
For peptide solutions that are water-soluble and not bacteriostatic, the membrane filtration method is applied. The sample is filtered through a 0.45 μm membrane that retains any microorganisms while allowing the liquid to pass through. The membrane is then transferred to — or washed with — culture media. This approach concentrates organisms from a larger sample volume, improving detection sensitivity. Direct inoculation (transferring the sample directly into media) is the alternative when membrane filtration is not feasible.
Inoculation into FTM and SCDM
The sample — whether via membrane or direct inoculation — is introduced into both Fluid Thioglycollate Medium and Soybean-Casein Digest Medium. Both media are required by USP ⟨71⟩ because no single medium supports all relevant microorganism types. FTM supports anaerobic and aerobic bacteria; SCDM supports aerobic bacteria plus fungi and yeast. Omitting either medium leaves an entire class of potential contaminants undetected.
14-Day Incubation at Specified Temperatures
FTM vessels are incubated at 30–35°C to support optimal bacterial growth. SCDM vessels are incubated at 20–25°C, a lower temperature that favors fungal and yeast growth while still supporting aerobic bacteria. All vessels are incubated for a minimum of 14 days. USP ⟨71⟩ is explicit: early termination at day 7 or day 10 is not compliant. Some slow-growing organisms — particularly certain fungi — require the full 14-day period to produce visible growth.
Observation, Interpretation, and Reporting
Each vessel is examined at Day 3, Day 7, and Day 14 for visible turbidity (cloudiness), precipitation, or other signs of microbial growth. Clear media at Day 14 in all vessels = PASS. Any visible growth triggers an investigation — the initial contamination must be attributed to either a true batch failure or a laboratory error (false positive from environmental contamination during testing). Only documented aseptic failure during testing permits a retest. True batch contamination results in batch rejection.
The Two Culture Media: FTM and SCDM Explained
The selection and validation of culture media is one of the most critical — and most commonly underspecified — aspects of peptide sterility testing. USP ⟨71⟩ mandates two specific media types because no single medium can reliably support the full spectrum of microorganisms the test is designed to detect. Each medium has a defined growth spectrum, incubation temperature, and validation requirement.
Before each lot of culture media is used for routine sterility testing, it must pass Growth Promotion Testing (GPT). GPT inoculates each medium with a low-level (NMT 100 CFU) challenge of specific USP organisms and confirms that clear growth is observed within the incubation period. Media that fails GPT cannot be used for sterility testing — any results from non-validated media are scientifically invalid. If a vendor's sterility COA does not reference media lot numbers or GPT results, this is a documentation gap that should prompt further inquiry.
The 14-Day Incubation Protocol and Observation Schedule
The 14-day incubation period is not arbitrary — it reflects the time required for slow-growing organisms, particularly certain fungi and some psychrotrophic bacteria, to produce visible turbidity at the relevant incubation temperatures. Shorter incubation periods miss these organisms and are not USP ⟨71⟩ compliant for release testing.
Why 14 Days — The Science Behind the Duration
- Slow-growing fungi — Some Aspergillus and Penicillium species require up to 10–12 days to produce visible mycelial growth in liquid culture at 20–25°C. A 7-day test would miss these organisms entirely.
- Low-level contamination — A vial contaminated with only 1–5 CFU may require several growth cycles before producing visible turbidity. Higher inoculum numbers become visible sooner; low-level contamination requires the full 14 days for reliable detection.
- Stressed organisms — Microorganisms exposed to partial sterilization treatments may be metabolically compromised. These "sublethally injured" cells require longer recovery time before active growth resumes and becomes detectable.
- Psychrotrophic organisms — Cold-adapted bacteria that grow optimally at 15–20°C will grow slowly at the SCDM incubation temperature of 20–25°C. The full 14 days ensures sufficient growth for visual detection.
Sterility Test Methods: Membrane Filtration vs Direct Inoculation
USP ⟨71⟩ specifies two primary methods for performing the sterility test. The choice between them depends on the physical and chemical properties of the peptide product being tested.
Membrane Filtration (Preferred Method)
In the membrane filtration method, the peptide sample is filtered through a sterile 0.45 μm membrane filter. Any microorganisms present are retained on the membrane surface. The membrane is then either transferred directly to culture media vessels, or the filter housing is rinsed with media to wash the retained organisms into the media for incubation.
Advantages of membrane filtration:
- Can process larger sample volumes, improving detection sensitivity for low-level contamination
- Allows washing of bacteriostatic/fungistatic substances from the membrane before culture, reducing interference
- Preferred by USP ⟨71⟩ for aqueous solutions of injectable products
- More sensitive than direct inoculation for detecting sparse contamination
Direct Inoculation (Alternative Method)
In the direct inoculation method, a specified volume of the peptide sample is transferred directly into the culture media vessels without filtration. This method is used when the product cannot be filtered — for example, peptides that are oily, highly viscous, or in formulations incompatible with membrane filtration.
Limitations of direct inoculation:
- Lower sample volume can be tested compared to membrane filtration
- Antimicrobial properties of the product may inhibit microbial growth (bacteriostasis problem), requiring method suitability validation to neutralize the inhibition
- Less preferred for injectable peptides where maximum detection sensitivity is required
Before either method is used routinely, it must be validated to confirm that the product itself does not inhibit microbial growth in the test conditions — a phenomenon called bacteriostasis (for bacteria) or fungistasis (for fungi). Suitability testing inoculates the media with a low-level challenge organism in the presence of the product. If the product inhibits growth, the method must be modified (e.g., higher dilution, additional washing, neutralization agents) until inhibition is eliminated. This validation is product-specific and must be repeated whenever the formulation changes.
Sterility vs Endotoxin vs Bioburden Testing: Critical Differences
These three microbial quality tests are frequently confused, combined incorrectly, or used as substitutes for each other in inadequate quality programs. They are not interchangeable. Each test addresses a distinct safety question and is performed at a different stage of the manufacturing process. Here is the complete comparison:
| Parameter | Sterility Testing (USP ⟨71⟩) | Endotoxin / LAL (USP ⟨85⟩) | Bioburden Testing |
|---|---|---|---|
| What it detects | Viable microorganisms (bacteria, fungi, yeast) | Bacterial endotoxins (LPS fragments from Gram-negative bacteria) | Total count of viable microorganisms (pre-sterilization) |
| When performed | Post-sterilization or final product | Post-sterilization or final product | Pre-sterilization (during manufacturing) |
| Detects live bacteria | ✔ Yes — viable cells only | ✘ No — detects cell wall fragments (endotoxins survive after bacteria die) | ✔ Yes — colony count |
| Detects fungi/yeast | ✔ Yes (SCDM + 20-25°C) | ✘ No — LAL is endotoxin-specific | ✔ Yes (with appropriate media) |
| Detects endotoxins | ✘ No — endotoxins are not living organisms | ✔ Primary function | ✘ No |
| Pass criteria | No growth in either medium at Day 14 | Endotoxin level ≤ limit (EU/mg) by route | Colony count within batch specification (CFU/unit) |
| Time to result | 14 days minimum | 1–3 hours (gel-clot to kinetic turbidimetric) | 3–7 days (aerobic count) to 14 days (anaerobic) |
| Regulatory basis | USP ⟨71⟩ / Ph. Eur. 2.6.1 | USP ⟨85⟩ / Ph. Eur. 2.6.14 | USP ⟨1227⟩, ISO 11737-1 |
| Required for injectables? | ✔ Mandatory | ✔ Mandatory | ◑ Process control (not release test) |
| Can substitute the others? | ✘ No — different information | ✘ No — different information | ✘ No — different stage, different purpose |
A peptide can pass sterility testing (no viable microorganisms) while failing endotoxin testing (high bacterial endotoxin content from Gram-negative bacteria that were killed during sterilization but left endotoxins behind). Conversely, a product can pass endotoxin testing while failing sterility testing (viable bacteria present that don't produce detectable endotoxins, such as Gram-positive cocci). For injectable peptides, all three testing categories are required — not optional and not interchangeable.
Route of Administration and Sterility Risk Levels
The regulatory and clinical requirement for sterility testing is directly determined by the route of administration of the peptide product. The more direct the route of contact with sterile tissues or the bloodstream, the higher the sterility requirement — and the more rigorous the testing standard that applies.
Direct blood contact. Sterility mandatory. Both USP ⟨71⟩ sterility and USP ⟨85⟩ endotoxin testing required. Strictest standards.
Direct tissue injection. Sterility mandatory. Endotoxin testing required. Most research peptide injectables fall here.
CNS contact. The most stringent sterility requirements of any route — a single contamination event can be catastrophic. Beyond USP ⟨71⟩ in some cases.
Mucosal contact. Sterility recommended but not always mandated. Microbial limits testing (USP ⟨1111⟩) typically required at minimum.
Intact skin contact. Full sterility testing not typically required. Microbial limits specification (USP ⟨1111⟩) applies. Not suitable for broken skin.
Gastric acid + epithelial barrier. Full sterility testing generally not required. Non-sterile microbial limits apply. Most permissive standards.
What a Complete Peptide Sterility Test Report Must Contain
A sterility certificate is only credible if it documents the complete analytical context — not just a PASS result. Here is what every legitimate third-party peptide sterility test report must include, modeled against a sample document:
Red Flags in a Peptide Sterility Certificate
- No media lot numbers or growth promotion results — indicating media validation was not performed or not documented
- Result issued in less than 14 days — non-compliant with USP ⟨71⟩ incubation requirements; any certificate with a turnaround shorter than 14 days from test start is suspect
- Only one medium listed — both FTM and SCDM are required; a result from a single medium is not a valid USP ⟨71⟩ sterility test
- No method specified — membrane filtration or direct inoculation must be stated, along with the sample volume tested
- No laboratory accreditation — sterility testing requires validated facilities; unaccredited labs performing sterility tests outside a cleanroom cannot produce reliable results
- No method suitability statement — absence of bacteriostasis/fungistasis testing documentation means the method was never validated for the specific product
Need USP ⟨71⟩ Sterility Testing With a Credible Certificate?
PeptideValidation.com coordinates third-party USP ⟨71⟩ sterility testing through ISO/IEC 17025-accredited laboratories — with documented FTM and SCDM results, growth promotion validation, and full 14-day incubation. Your customers deserve verified safety data, not vendor assurances.
Request Sterility Testing → View Testing StandardsHow PeptideValidation.com Handles Peptide Sterility Testing
At PeptideValidation.com, sterility testing is coordinated through our network of ISO/IEC 17025-accredited microbiological testing laboratories with documented cleanroom facilities and USP ⟨71⟩-validated methods. Here is how we manage the process for every batch requiring sterility documentation:
Batch Assessment and Testing Plan
When a peptide batch is received and intended for an injectable or clinical application, we assess the required testing scope based on the route of administration, batch size, and regulatory context. We determine the number of containers required by USP ⟨71⟩, the sample volume per container, and the appropriate test method (membrane filtration for aqueous solutions). This plan is documented before any testing begins.
Sample Dispatch Under Controlled Conditions
Representative samples are pulled from the peptide batch under documented conditions and dispatched to the testing laboratory with a chain of custody document. We ensure cold chain integrity is maintained during transport (2–8°C for aqueous solutions) to prevent any change in microbial status between the batch and the point of testing. Chain of custody documentation connects every sample to its parent batch lot number.
Method Suitability Confirmation
Before the actual sterility test is initiated for a novel peptide product, our laboratory partners perform method suitability testing — confirming that the peptide formulation does not exhibit bacteriostatic or fungistatic activity at the test concentration. If inhibition is detected, the method is modified (dilution, increased wash steps, neutralizing agents) and re-validated. Only validated methods are used for release testing.
USP ⟨71⟩ Testing — Full 14-Day Protocol
The sterility test is performed using membrane filtration where appropriate, inoculating both FTM (30–35°C) and SCDM (20–25°C) media from validated lots with confirmed growth promotion results. All testing is performed by trained analysts in a Grade A laminar airflow workstation with ongoing environmental monitoring. Vessels are observed and documented at Day 3, Day 7, and Day 14.
Result Documentation and Certificate Generation
Upon completion at Day 14, the test results for both media are compiled into a complete sterility test report. The report documents media lot numbers, growth promotion results, incubation dates and temperatures, all observation data, method suitability status, and the pass/fail conclusion per USP ⟨71⟩ criteria. The certificate is reviewed by the laboratory's qualified person (QP) before release to us, and is then attached to the client batch COA package alongside HPLC purity and LC-MS identity data.
Integrated Safety Package — Sterility + Endotoxin + Purity + Identity
For peptides intended for injectable use, we coordinate the complete safety and quality testing package: HPLC purity, LC-MS identity, USP ⟨71⟩ sterility, and USP ⟨85⟩ endotoxin (LAL) testing. All four results are integrated into a single comprehensive COA, giving you — and your customers — the complete picture of chemical quality and microbiological safety in one document.
Common Sterility Testing Mistakes — and Why They Matter
Treating a 7-Day or 10-Day Incubation as USP Compliant
USP ⟨71⟩ is unambiguous: the minimum incubation period is 14 days. A certificate stating "sterility testing performed — 7 days — no growth" is not a valid USP ⟨71⟩ sterility test. It is a shorter, non-standard microbiological check that misses slow-growing organisms. This is one of the most common shortcuts seen in low-cost testing operations, and the resulting certificates offer a false sense of safety assurance.
Using Only One Culture Medium
Both FTM and SCDM are mandatory under USP ⟨71⟩. FTM alone won't detect fungi. SCDM alone won't reliably detect anaerobic bacteria. A certificate documenting results from only one medium — however labeled — does not constitute a complete USP ⟨71⟩ sterility test. Anaerobic contamination from Clostridium species, for example, would be entirely missed without FTM.
Skipping Method Suitability Testing
Many synthetic peptides contain sequences with intrinsic antimicrobial activity — certain cationic or amphiphilic sequences inhibit bacterial growth in culture media, producing false-negative sterility test results. If method suitability testing was never performed for the specific peptide formulation, a PASS result may simply mean the peptide killed the contaminating organisms before growth was visible — not that the product was sterile. This invalidates the test entirely.
Performing Sterility Testing in Non-Cleanroom Environments
Sterility testing must be performed in validated Grade A (ISO 5) environments with documented environmental monitoring. A positive result in a contaminated testing environment cannot be attributed to the product versus the laboratory environment without extensive investigation. Many budget testing services perform sterility testing in uncontrolled bench environments — this invalidates any result they produce, positive or negative.
Confusing Sterility Testing With Endotoxin Testing
A peptide COA that documents only endotoxin (LAL) testing and claims this covers sterility has made a fundamental analytical error. Endotoxin testing detects bacterial lipopolysaccharide fragments — it does not detect viable microorganisms, fungi, yeast, or Gram-positive bacteria. The two tests answer different questions and are both mandatory for injectable peptides. Substituting one for the other leaves critical safety questions unanswered.
Not Testing After Reconstitution or Final Formulation
Some vendors perform sterility testing on the dry lyophilized powder but do not validate the reconstitution process itself. If the bacteriostatic water used for reconstitution is contaminated, or if the reconstitution protocol introduces contamination at point-of-use, a PASS result on the dry powder provides no safety assurance for the final reconstituted solution. For products where reconstitution is part of the final preparation, sterility testing of the reconstituted product — or rigorous container/closure integrity testing — is also required.
Who Needs Sterility Testing for Peptides?
If your peptide product is used in any context where it will contact sterile tissues, be injected, or be administered to a patient or research subject, sterility testing is not optional — it is a mandatory safety requirement. The following entities have the most direct need:
If your peptide is intended exclusively for oral or topical administration without any injectable application, full USP ⟨71⟩ sterility testing may not be required — but microbial limit specifications (USP ⟨1111⟩) still apply, and you should document your reasoning. When in doubt, the conservative position is always to test.
Benefits of Third-Party Peptide Sterility Testing
The most fundamental benefit: verified sterility means the people using or administering your peptide are not exposed to microbial contamination that could cause infection, fever, or worse. This is the non-negotiable reason sterility testing exists.
A documented USP ⟨71⟩ sterility certificate from an accredited laboratory creates an auditable safety record. In the event of an adverse event, regulatory inquiry, or product liability claim, it demonstrates that you met the applicable safety standard.
Clinics, compounding pharmacies, hospitals, and institutional purchasers require verified sterility documentation before they will source injectable peptides. Without a credible sterility certificate, entire market segments are closed to your product.
Independent sterility testing holds your peptide manufacturer accountable for the cleanliness of their synthesis, filling, and packaging operations. You'll identify contamination issues before they reach your customer — not after an adverse event surfaces it.
Combining sterility testing with HPLC purity, LC-MS identity, and endotoxin testing gives you a four-dimensional quality record — chemical purity, molecular identity, microbial sterility, and endotoxin safety — that represents the gold standard for injectable peptide documentation.
In a peptide market saturated with vendors offering purity claims and little else, a brand that publishes verifiable sterility certificates builds a level of credibility that competitors relying on vendor assurances cannot match. Safety documentation is a durable competitive advantage.
Final Thoughts: Sterility Testing Is the Safety Floor, Not the Ceiling
The peptide industry's quality conversation centers heavily on HPLC purity and LC-MS identity — and those tests are essential. But for any peptide used in an injectable application, stopping there is stopping before the finish line. Chemical purity and molecular identity confirm what the product is. Sterility testing confirms that it is safe to administer to a living body.
USP ⟨71⟩ sterility testing — performed correctly, in a validated cleanroom environment, with both required media, for the full 14-day incubation period, with documented growth promotion and method suitability — is not a formality. It is the analytical safeguard that stands between a contaminated batch and a patient adverse event.
The cost of proper sterility testing is modest relative to the cost of the harm its absence can cause: infections, hospitalizations, regulatory sanctions, and the permanent reputational damage of a product linked to a patient safety failure.
At PeptideValidation.com, sterility testing is coordinated as part of a complete quality package for every injectable batch — not as a checkbox, but as the mandatory safety gate that injectable peptides require. We do not release injectable peptides without it, and we do not accept certificates that don't meet USP ⟨71⟩ documentation standards.
If your injectable peptide products don't come with verified, compliant sterility certificates — the gap you're carrying is not a quality gap. It is a safety gap. And the only way to close it is to test.
Get USP ⟨71⟩ Sterility Certified Peptides — With a Certificate That Proves It
PeptideValidation.com delivers full sterility test certificates alongside HPLC purity, LC-MS identity, and LAL endotoxin results. One comprehensive COA. Four dimensions of quality and safety — verified, documented, and defensible.
Request Safety Testing → View Our Testing StandardsFrequently Asked Questions About Peptide Sterility Testing
The questions peptide vendors, compounding pharmacies, research labs, and DTC brands ask most about sterility testing requirements, USP ⟨71⟩, and microbial safety documentation.